IFI-M · ABK Tri-Axis Dominant-Primary Series

Specimen SS-F-M3-02741 // MULTI-AXIS · IFI-M

ABK Tri-Axis Dominant-Primary Series IV-AG

Vitis vinifera

Grape

Tier IVABK Tri-Axis Dominant-Primary Series

Target Trait

2.38×

fold-change

Astringency-dominant tri-axis B+K modulated fold-change

Technical Specifications

SKU

SS-F-M3-02741

Genomic Edits

11

GC Content

47.6%

Construct Length

6,007 bp

Promoter System

Tissue-specific 2A11

Expression System

Agrobacterium-mediated T-DNA

Host Strain

EHA105

Receptor Target

Polyphenol-astringency axis + TAS2R38 (suppression) + CaSR

IFI Score

238

Pathway Edits

  • Polyphenol-astringency axis pathway primary gene cluster for astringency (IFI-A) tri-axis component
  • TAS2R38 (suppression) pathway primary gene cluster for bitter-attenuation (IFI-B) tri-axis component
  • CaSR pathway primary gene cluster for kokumi (IFI-K) tri-axis component
  • Tri-axis metabolic flux partitioning hub for concurrent ABK pathway operation
  • Cross-pathway regulatory circuit for astringency-dominant ABK triple-axis expression
  • Cofactor regeneration system (NADPH, ATP, acetyl-CoA) supporting triple-axis concurrent production

Key Interventions

Triple-axis receptor co-activation: Polyphenol-astringency axis, TAS2R38 (suppression), and CaSR pathways simultaneously engineeredAstringency-dominant tri-axis expression strategy (ABK) with cross-pathway flux managementT-DNA binary vector 2A11 for stable genomic integration of multi-axis construct stack

IFI Subscale Profile

IFI Profile

IFI-S
—
IFI-U
—
IFI-B
—
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
—
IFI-F
—

Use Case

Tier IV ABK triple-axis construct for advanced multi-modal sensory architecture combining astringency, bitter-attenuation, and kokumi axes. Suitable for ultra-premium ingredient formulation requiring certification across three simultaneous IFI receptor pathways.

License

$3999 · Tier IV License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?